Samsung C&T has invested $10 million in C2N Diagnostics, a U.S. firm specializing in blood tests for Alzheimer’s disease, leveraging its innovative technology for the future of diagnostic solutions.
Target Company Overview
Samsung C&T, through its life sciences fund established with its subsidiaries Samsung Biologics, Samsung Bioepis, and Samsung Venture Investment, announced an investment of $10 million in C2N Diagnostics, a U.S.-based company. C2N Diagnostics specializes in the precision measurement and analysis of low-abundance protein biomarkers found in blood.
Utilizing its proprietary technology, C2N Diagnostics has developed a blood test for the diagnosis of Alzheimer’s disease. The company has not only demonstrated its technical capabilities through its participation in clinical trials for Alzheimer’s treatments but is also involved in various clinical trials for other central nervous system disorders worldwide.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the United States
The diagnostic industry in the United States is at the forefront of innovation, primarily driven by advances in biotechnology and the increasing demand for personalized m
Similar Deals
Marlin Equity Partners → Intelligent Locations
2025
Rittenhouse Ventures → S2N Health, Inc.
2025
삼성물산
invested in
C2N Diagnostics
in 2025
in a Other VC deal
Disclosed details
Transaction Size: $10M